• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Comera Life Sciences Holdings Inc.

    1/10/23 4:30:54 PM ET
    $CMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMRA alert in real time by email
    SC 13G 1 d387306dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Comera Life Sciences Holdings, Inc.

    (Name of Issuer)

    Common stock, par value $0.0001 per share

    Warrants

    (Title of Class of Securities)

    20037C108

    (CUSIP Number)

    January 4, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Freebird Partners LP

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Texas

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      1,313,423 (1)

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      1,313,423 (1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,313,423 (1)(2)

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      5.71%(2)

    12  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Includes (i) 570,181 shares of common stock, par value $0.0001 per share (the “Common Stock”), of which 40,325 shares of Common Stock (the “Earn-out Shares”) were issued to Freebird Partners LP, a Texas limited partnership (“Freebird Partners”) pursuant to that certain Business Combination Agreement dated January 31, 2022 (the “Business Combination Agreement”), by and among OTR Acquisition Corp., Comera Life Sciences Holdings, Inc. (the “Issuer”), CLS Sub Merger 1 Corp., CLS Sub Merger 2 Corp., and Comera Life Sciences Inc., and are currently held in escrow until the occurrence of certain events, as described in the Business Combination Agreement, filed as Exhibit 2.1 to the Issuer’s Prospectus Supplement No. 1 to Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on August 15, 2022, and (ii) 371,621 warrants (the “Warrants”) representing the right to purchase two shares of Common Stock (the “Warrant Shares”) of the Issuer at an exercise price of $1.23 per Warrant Share, directly beneficially owned by Freebird Partners. Freebird Investments LLC, a Texas limited liability company (“Freebird Investments”), serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

    (2)

    Such percentage is based on an aggregate of 22,265,463 shares of Common Stock and 743,242 Warrants Shares of the Issuer underlying the Warrants held by Freebird Partners, which is calculated by adding (i) 22,265,463 shares of Common Stock issued and outstanding as of January 5, 2022 as provided by the Issuer and (ii) 743,242 Warrant Shares underlying the Warrants held by Freebird Partners that the Issuer sold pursuant to that certain Securities Purchase Agreement dated January 2, 2023, as announced in the Issuer’s Current Report on Form 8-K filed with the SEC on January 4, 2023.


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Freebird Investments LLC

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Texas

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      1,313,423 (1)

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      1,313,423 (1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,313,423 (1)(2)

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      5.71%(1)(2)

    12  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Includes (i) 570,181 shares of Common Stock, of which 40,325 are Earn-out Shares, which were issued to Freebird Partners pursuant to that certain Business Combination Agreement and are currently held in escrow until the occurrence of certain events, as described in the Business Combination Agreement, filed as Exhibit 2.1 to the Issuer’s Prospectus Supplement No. 1 to Form S-1 filed with the SEC on August 15, 2022, and (ii) 371,621 Warrants representing the right to purchase two Warrant Shares of the Issuer at an exercise price of $1.23 per Warrant Share, directly beneficially owned by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Mr. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

    (2)

    Such percentage is based on an aggregate of 22,265,463 shares of Common Stock and 743,242 Warrants Shares of the Issuer underlying the Warrants held by Freebird Partners, which is calculated by adding (i) 22,265,463 shares of Common Stock issued and outstanding as of January 5, 2022 as provided by the Issuer and (ii) 743,242 Warrant Shares underlying the Warrants held by Freebird Partners that the Issuer sold pursuant to that certain Securities Purchase Agreement dated January 2, 2023, as announced in the Issuer’s Current Report on Form 8-K filed with the SEC on January 4, 2023.


      1    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only)

     

      Curtis Huff

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      1,313,423 (1)

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      1,313,423 (1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,313,423 (1)(2)

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11  

      Percent of Class Represented by Amount in Row (9)*

     

      5.71%(1)(2)

    12  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Includes (i) 570,181 shares of Common Stock, of which 40,325 are Earn-out Shares, which were issued to Freebird Partners pursuant to that certain Business Combination Agreement and are currently held in escrow until the occurrence of certain events, as described in the Business Combination Agreement, filed as Exhibit 2.1 to the Issuer’s Prospectus Supplement No. 1 to Form S-1 filed with the SEC on August 15, 2022, and (ii) 371,621 Warrants representing the right to purchase two Warrant Shares of the Issuer at an exercise price of $1.23 per Warrant Share, directly beneficially owned by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Mr. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

    (2)

    Such percentage is based on an aggregate of 22,265,463 shares of Common Stock and 743,242 Warrants Shares of the Issuer underlying the Warrants held by Freebird Partners, which is calculated by adding (i) 22,265,463 shares of Common Stock issued and outstanding as of January 5, 2022 as provided by the Issuer and (ii) 743,242 Warrant Shares underlying the Warrants held by Freebird Partners that the Issuer sold pursuant to that certain Securities Purchase Agreement dated January 2, 2023, as announced in the Issuer’s Current Report on Form 8-K filed with the SEC on January 4, 2023.


    Item 1.

     

    (a)

    Name of Issuer

    Comera Life Sciences Holdings, Inc.

     

    (b)

    Address of Issuer’s Principal Executive Offices

    12 Gill Street, Suite 4650

    Woburn, Massachusetts 01801

     

    Item 2.

     

    (a)

    Name of Person Filing

    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):

    • Freebird Partners LP, a Texas limited partnership;

    • Freebird Investments LLC, a Texas limited liability company;

    • Curtis W. Huff, an individual and a citizen of the United States of America.

    Freebird Investments LLC is the general partner of Freebird Partners LP, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Freebird Partners LP.

    Curtis Huff is the sole member of Freebird Investments LLC, which is the general partner of Freebird Partners LP, and as a result, may be deemed to share voting and dispositive power with respect to the securities held by Freebird Partners LP.

    Freebird Partners LP, Freebird Investments LLC, and Mr. Huff have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    (b)

    Address of Principal Business Office or, if none, Residence

    The address of the principal business office for each of the Reporting Persons is:

    2800 Post Oak Blvd, Suite 2000

    Houston, TX 77056

     

    (c)

    Citizenship

    See Row 4 of cover page for each Reporting Person.

     

    (d)

    Title of Class of Securities

    Common stock, par value $0.0001 per share.

     

    (e)

    CUSIP Number

    20037C108


    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount Beneficially Owned

    See Row 9 of cover page for each Reporting Person.

     

    (b)

    Percent of Class

    See Row 11 of cover page for each Reporting Person.

     

    (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or to direct the vote

    See Row 5 of cover page for each Reporting Person.

     

      (ii)

    shared power to vote or to direct the vote

    See Row 6 of cover page for each Reporting Person.

     

      (iii)

    sole power to dispose or to direct the disposition of

    See Row 7 of cover page for each Reporting Person.

     

      (iv)

    shared power to dispose or to direct the disposition of

    See Row 8 of cover page for each Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    January 10, 2023

    FREEBIRD PARTNERS LP

    By: Freebird Investments LLC, its general partner

     

    By:  

    /s/ Curtis Huff

    Name: Curtis Huff
    Title: Chairman and President

     

    FREEBIRD INVESTMENTS LLC
    By:  

    /s/ Curtis Huff

    Name: Curtis Huff
    Title: Chairman and President
    CURTIS HUFF
    By:  

    /s/ Curtis Huff

     

    Get the next $CMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option

      WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to

      1/4/24 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Announces Process Exploring Strategic Alternatives

      WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a

      12/6/23 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

      WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

      11/13/23 8:00:19 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Konar Shameek

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      2/2/24 7:48:13 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Konar Shameek claimed ownership of 1,001,064 shares (SEC Form 3)

      3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      2/2/24 7:47:03 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Denny George P Iii

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      1/11/24 7:14:17 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:18 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:27 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:16 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Comera Life Sciences Holdings Inc.

      SC 13D - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      1/5/24 7:16:15 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Comera Life Sciences Holdings Inc. (Amendment)

      SC 13D/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      9/7/23 8:05:22 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Comera Life Sciences Holdings Inc. (Amendment)

      SC 13G/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      9/6/23 4:24:17 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Campbell Michael Gerard bought $708 worth of shares (10,000 units at $0.07), increasing direct ownership by 40% to 35,000 units (SEC Form 4)

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      11/28/23 4:25:36 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Financials

    Live finance-specific insights

    See more
    • Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

      – Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera's global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – –   Completed previously announced $4.1 million private placement of shares of Comera's common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety,

      11/9/23 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

      – Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera's request for the continued listing of its common stock, subject to Comera's satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN

      8/10/23 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights

      – Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulation – – Expanded Comera's patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 (GLOBE NEWSWIRE) --  Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the first quarter ende

      5/11/23 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

      WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

      11/13/23 8:00:19 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS. ROMAN FLECK AND NEAL I. MUNI TO BOARD OF DIRECTORS

      Appointment of veteran industry executives adds broad experience to HDAX team. MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member. "HDAX's platform technology has great potential to deliver breakthrough treatments where there is high unmet need.""We are please

      4/11/23 9:04:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Appoints Janice Marie McCourt as Chief Business Officer

      WOBURN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced the appointment of Janice Marie McCourt as Chief Business Officer. In her role at Comera, Ms. McCourt will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities, and driving the execution of the Company's commercial strategy. Ms. McCourt will report to Jeffrey Hackman, Chairman and CEO, and serve on the Company's executive leadership te

      11/9/22 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care